Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 2CNS 2NET 1

Conditions

Neuroendocrine Tumors 3Paraganglioma 2Neuroblastoma 2Carcinoid Tumor 2Tumor Positron-Emission Tomography 1Pheochromocytoma 1Meningioma 1Medulloblastoma 1

Interventions

lutetium Lu 177 dotatate 2gallium Ga 68 dotatate 2olaparib 1Nivolumab 1Magnetic Resonance Spectroscopy 1Iodine-131 13-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Paraganglioma × gallium Ga 68 dotatate × Clear all
NCT06427798 2026-03-10

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
66 enrolled
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT02177773 2019-11-12

DOTA-TOC

University of California, San Francisco

Phase 1/2 Terminated
300 enrolled 5 charts
CNSEndocrineNET

Carcinoid Tumor, Neuroblastoma, Paraganglioma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡